INTS vs MRK · $7.7M cap vs P/E 33, rev $65.01B
Intensity Therapeutics, Inc. Common stock (INTS) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
INTS does not have a complete income-statement cache yet.
Latest reported MRK revenue for 2025-12-31 was $65.01B. Net income was $18.25B. Revenue was up 1.3% from 2024-12-31 to 2025-12-31. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
INTS currently screens at market cap $7.7M. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the INTS and MRK stock pages for the full models.
Not investment advice.